The European Commission authorised, on 10 November, a seventh vaccine against Covid-19: VidPrevtyn Beta. This vaccine was developed by Sanofi and GSK. The European Commission’s formal decision is based on a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), issued the same day. VidPrevtyn Beta is a recombinant protein vaccine formulated with the Beta variant antigen and adjuvanted with GSK’s pandemic adjuvant.